| Popis: |
Constantina A Bounia,1 Eftichia N Theodoropoulou,1 Stamatic-Nick C Liossis1,2 1Division of Rheumatology, Patras University Hospital, Patras, Greece; 2Department of Internal Medicine, University of Patras Medical School, Patras, GreeceCorrespondence: Stamatic-Nick C LiossisDiv. of Rheumatology, Patras University Hospital, GR 26500, Rion, Patras, GreeceTel +30 2613 603 693Fax +30 2610 993 982Email snliossis@med.upatras.grAbstract: Renal failure or acute/chronic kidney damage may present as a clinical manifestation of rheumatic diseases. In addition treatment with DMARDs or biologic drugs may induce nephrotoxicity. In this case-based review, we present two patients with SpA under anti-TNF-α treatment admitted to our hospital because of renal failure and proteinuria. We review previously published yet isolated cases of TNF-α blocker-induced glomerular disease in patients with SpA. Renal manifestations are occasionally seen in patients with ankylosing spondylitis and psoriatic arthritis with IgA nephropathy being the most common of them. Anti-TNF-α agents although reportedly used for the treatment of glomerular nephropathy as a disease manifestation, they have been considered responsible for provoking renal damage in some cases. A diagnostic approach for patients with SpA treated with anti-TNF-α agents presenting with renal manifestations is proposed herein.Keywords: spondylarthritides, glomerular disease, proteinuria, kidney biopsy, anti-TNF-alpha agents |
